NASDAQ: ZVRA ZEVRA THERAPEUTICS, INC. 8-K

Zevra sells AZSTARYS portfolio to Commave for $50M, repays $63M debt facility in full

Filed March 16, 2026 · Period ending March 12, 2026 · ~1 min read

Key Changes

  • high

    Zevra sold its SDX portfolio including AZSTARYS and KP1077 to Commave for $50M cash ($25M upfront, $20M within 10 days, $5M upon records delivery), settling Delaware litigation and terminating their 2019 license agreement.

  • high

    Company repaid entire $63M senior secured loan facility on March 12, three years early, terminating the Credit Agreement and releasing all liens on substantially all company and subsidiary assets.

  • medium

    Parties agreed to dismiss Delaware litigation with prejudice within three business days and provided mutual releases for all claims related to the AZSTARYS License Agreement.

1 more material change plus the full narrative summary — create a free account to see the rest. Takes 30 seconds.

Partner

Trade ZVRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 8, 2026 7:21 PM